We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

Back to rankings

0 hedge funds and large institutions have $0 invested in Juniper Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $44.1M → $0 (-$44.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$6.54M
2
JAM
JW Asset Management
Florida
-$3.71M
3
BlackRock
BlackRock
New York
-$3.65M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.52M
5
BCM
Bridgeway Capital Management
Texas
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
– -$6.54M -752,173 Closed
JAM
2
JW Asset Management
Florida
– -$3.71M -426,903 Closed
BlackRock
3
BlackRock
New York
– -$3.65M -419,357 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$3.52M -405,196 Closed
BCM
5
Bridgeway Capital Management
Texas
– -$3.19M -366,751 Closed
KAM
6
Krensavage Asset Management
New York
– -$2.68M -308,478 Closed
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
– -$2.4M -275,506 Closed
AG
8
Algert Global
California
– -$2.22M -255,131 Closed
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
– -$1.97M -225,919 Closed
AIC
10
AWM Investment Company
New York
– -$1.74M -200,000 Closed
PCM
11
Perritt Capital Management
Illinois
– -$1.3M -149,463 Closed
ACM
12
Ativo Capital Management
Illinois
– -$1.14M -130,642 Closed
HA
13
Heartland Advisors
Wisconsin
– -$1.09M -125,000 Closed
OAM
14
Oxford Asset Management
United Kingdom
– -$886K -100,151 Closed
OAM
15
Oberweis Asset Management
Illinois
– -$813K -93,400 Closed
HIM
16
Hillsdale Investment Management
Ontario, Canada
– -$749K -86,139 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$638K -73,410 Closed
SIM
18
Spark Investment Management
New York
– -$456K -52,500 Closed
Northern Trust
19
Northern Trust
Illinois
– -$454K -52,261 Closed
GC
20
Globeflex Capital
California
– -$350K -40,200 Closed
OSAM
21
O'Shaughnessy Asset Management
Connecticut
– -$304K -34,967 Closed
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$282K -32,450 Closed
Jacobs Levy Equity Management
23
Jacobs Levy Equity Management
New Jersey
– -$258K -29,701 Closed
Squarepoint
24
Squarepoint
New York
– -$244K -28,100 Closed
Deutsche Bank
25
Deutsche Bank
Germany
– -$236K -27,173 Closed
1
2

JNP Hedge Fund Activity: Q3 2018 in Review

0 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q3 2018, worth a combined $0 — down 100% from $44.1M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of JNP and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $6.54M sold.

  • 0 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q3 2018, down from 48 in Q2 2018.
  • Funds reported $0 of Juniper Pharmaceuticals, Inc. Common Stock stock for Q3 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 47 closed out, a net change of -47 holders.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Renaissance Technologies, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2018.